Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2012-07-15 Call Transcript
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Pharmaxis Quarterly Investor Conference Call 1 page
Call Transcript Classification · 90% confidence The document is a media release announcing an upcoming investor teleconference to discuss the June 2012 Quarterly Report. It states the report will be released on 17 July 2012 and the conference call will be held on 18 July 2012. The document does not contain the actual quarterly financial data or analysis but rather provides details on the timing and access for the call. This fits the definition of a Call Transcript announcement or a Call Transcript itself. However, since this is a pre-call announcement and not the transcript of the call, it is best classified as a Call Transcript (CT) category because it is directly related to the conference call event. The document length is short and it is not the report itself, so it is not an Interim/Quarterly Report (IR).
2012-07-15 English
Ceasing to be a substantial holder 3 pages 31.5KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 605' and references 'Corporations Law Section 671B' which relates to substantial shareholder notices. The content details a notice of ceasing to be a substantial holder for PHARMAXIS LIMITED, including dates of changes in shareholding and relevant interests. This type of filing is a notification about changes in significant share ownership levels, specifically when a holder ceases to be substantial. It is not a financial report, earnings release, or management information. It fits the definition of a Major Shareholding Notification (MRQ). The document length is 6743 characters, which is sufficient for a detailed notification. Therefore, the correct classification is MRQ with high confidence.
2012-07-09 English
Becoming a substantial holder 7 pages 236.4KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 Notice of initial substantial holder under Corporations Law Section 671B. It details the substantial shareholding of UBS AG and its related bodies corporate in Pharmaxis Limited, including voting power, nature of relevant interests, associates, and addresses. This type of filing is a notification of changes in significant share ownership levels, which corresponds to a Major Shareholding Notification. The document is not a financial report, earnings release, or management report, but a regulatory disclosure about shareholding thresholds being crossed.
2012-07-04 English
Ceasing to be a substantial holder 3 pages 50.2KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 Notice of ceasing to be a substantial holder under Corporations Law Section 671B. It details changes in substantial shareholding interests, including dates and nature of changes in voting securities. This type of filing is a notification about changes in major share ownership levels, specifically when a holder ceases to be substantial. It is not a financial report, earnings release, or management report. It fits the definition of a Major Shareholding Notification (MRQ). The document length and content confirm it is a substantive notification rather than a brief announcement or certification.
2012-07-03 English
Appendix 3B - Exercise of Employee Options 11 pages 94.4KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It details the issuance of fully paid ordinary shares upon exercise of options under an employee option plan, including the number of securities issued, exercise prices, and dates. The document references ASX rules and is a formal announcement to the Australian Securities Exchange regarding a capital raising event through option exercises. There are no financial statements, management discussion, or earnings data present. The content fits the definition of a Capital/Financing Update, as it provides updates on company fundraising and capital structure changes. The document length is substantial (15,000 characters), but the content is clearly an announcement of a new share issue rather than a full financial report or regulatory filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2012-07-01 English
Appendix 3B - Grant of Employee Performance Rights 12 pages 99.5KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard announcement to the Australian Securities Exchange (ASX) regarding a new issue of securities, specifically unlisted employee options (Performance Rights) over ordinary shares. It details the number of securities issued, terms, issue price, purpose, and other related information. This type of document is a capital/financing update as it relates to the issuance of new securities and changes in capital structure. It is not a full financial report, earnings release, or management report, nor is it a regulatory filing or announcement of a report publication. The document length is substantial and contains detailed information about the securities issued, consistent with a Capital/Financing Update.
2012-07-01 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.